14.04.2016 • NewsDede WillamsoncologyMerck

Maya Martinez-Davis to Head Oncology at Merck KGaA

With immediate effect, Merck KGaA has appointed Maya Martinez-Davis (46) as global head of oncology for its biopharma business, succeeding Andrew Schiermeier. She will be based in Billerica, Massachusetts, USA, and report to Rehan Verjee, chief marketing and strategy officer of Merck’s Healthcare business.

The new appointee’s responsibilities will include defining integrated global oncology strategies and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck and currently managed under a strategic alliance with Pfizer

Before joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade and prior to that held senior-level and director-level positions with Aventis Pharma in oncology.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.